The University of Southern California (USC) was awarded a $211,247 Project Grant by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to conduct a Phase II randomized clinical trial evaluating the use of tirzepatide, a dual GLP-1/GIP receptor agonist, for treating individuals with co-occurring alcohol use disorder and overweight/obesity. This 2-year study aims to expedite research on the potential of tirzepatide, a novel FDA-approved treatment for obesity, to also reduce alcohol consumption in this high-risk population. The research project will measure the effects of tirzepatide on alcohol use, weight, and cardiometabolic outcomes in adults with the comorbid conditions. The findings from this study could help identify an effective treatment approach for this challenging clinical presentation and have significant long-term public health impact.
Generated 1/28/25, 9:35 AM